. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in first-generation GLP-1s.

Can Dual Agonists Deliver Better Outcomes?

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, describes the immediate and long-term impacts of this potential levy on pharma imports.

The Ripple Effect of 200% Tariffs on US Drug Supply and Pricing

In the first part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, describes the US payer ecosystem’s level of preparedness to support broader access and long-term affordability for these therapies.

Coverage Gaps and Challenges Ahead for Obesity Drugs

In the final part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, offers communication strategies for staying confident in genuine pharmaceuticals while also remaining vigilant against counterfeit threats.

Balancing Awareness and Assurance

In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving

How Competition, Access, and Reimbursement Will Shape the Next Wave of Innovation

In the fourth part of this roundtable discussion, a panel of subject matter experts dive into data exchange challenges relating to the Drug Supply Chain Security Act.

Peer Exchange: How DSCSA Is Transforming Supply Chain Data Exchange (Episode 4)

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines. 

The Hidden Challenge of Reporting Counterfeit Medicines

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

The Biosimilar Void

In the third part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, recommends regulatory or verification mechanisms that can help safely legitimize online medicine procurement.

Cracking Down on Illegal Online Pharmacies

In the second part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, explains how the private sector should strategically support and scale efforts to ensure that HCPs globally receive substandard and falsified medicine detection training. 